SIGA TECHNOLOGIES INC
SIGANasdaq
$3.44
↓ -3.4%Jul 17 close · end-of-day
Price
1Y↓ -42.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$246.5M
Enterprise Value
$100.9M
P/E
12.3
P/S
2.6
P/B
1.6
EV/EBITDA
4.8
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$93.8M
Net Income (TTM)
$20.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
22.0%
Net Margin
21.6%
ROE
13.3%
ROIC
256.1%
Debt / Equity
—
Net Cash
$145.6M
Return 1Y
-42.0%
Company profile
SIGA Technologies, Inc. focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
- CEO
- Phillip L. Gomez
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- New York
- Website
- siga.com
Management & directors
- Miller Larry R.General Counsel
- Hruby Dennis EEVP & Chief Scientific Officer
- Luckshire Daniel JExecutive VP & CFO
- Nguyen DiemChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
SIGA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$6.2M↓ -11.3%
Diluted EPS-$0.05↑ +400.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $125.0M | $133.7M | $110.8M | $139.9M | $138.7M | $94.6M |
| Gross profit | — | — | — | — | — | — |
| Operating income | $84.5M | $89.1M | $42.7M | $83.6M | $70.0M | $23.7M |
| Net income | $56.3M | $69.5M | $33.9M | $68.1M | $59.2M | $23.3M |
| Diluted EPS | $0.71 | $0.91 | $0.46 | $0.95 | $0.82 | $0.32 |
| Operating cash flow | $71.5M | $11.5M | $41.6M | $94.8M | $48.8M | $43.5M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 67.6% | 66.7% | 38.5% | 59.8% | 50.4% | 25.1% |
| Net margin | 45.1% | 52.0% | 30.6% | 48.6% | 42.7% | 24.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $21.8M | $10.0M | $81.5M | $7.0M | $81.1M | $2.6M | $3.8M | $6.2M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $1.1M | $542,087.00 | $57.1M | -$2.3M | $45.7M | -$10.2M | -$9.5M | -$5.3M |
| Net income | $1.8M | $1.3M | $45.8M | -$408,223.00 | $35.5M | -$6.4M | -$5.4M | -$3.5M |
| Diluted EPS | $0.03 | $0.02 | $0.63 | -$0.01 | $0.49 | -$0.09 | -$0.07 | -$0.05 |
| Operating cash flow | $6.0M | -$7.4M | $56.3M | $7.1M | $63.1M | -$9.8M | -$16.9M | -$8.7M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 5.0% | 5.4% | 70.1% | -32.0% | 56.3% | -390.2% | -250.4% | -85.2% |
| Net margin | 8.4% | 13.4% | 56.2% | -5.8% | 43.7% | -243.0% | -143.1% | -55.3% |
Company news
May 22, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-09 | Phillips Holly L. | D | 7,235 | $4.39 | $31,761.65 | filing |
| 2026-06-09 | Marshall Joseph W III | D | 7,235 | $4.39 | $31,761.65 | filing |
| 2026-06-09 | Nemirovsky Julian | D | 7,235 | $4.39 | $31,761.65 | filing |
| 2026-06-09 | Ford Harold Eugene Jr. | D | 7,235 | $4.39 | $31,761.65 | filing |
| 2026-06-09 | DURNAN JAYMIE A | D | 7,235 | $4.39 | $31,761.65 | filing |
| 2026-06-09 | KEANE JOHN M | D | 7,235 | $4.39 | $31,761.65 | filing |
| 2026-06-09 | Nabel Gary J. | D | 7,235 | $4.39 | $31,761.65 | filing |
| 2026-06-09 | Marshall Joseph W III | Option exercise | 24,116 | — | — | filing |
| 2026-06-09 | KEANE JOHN M | Option exercise | 24,116 | — | — | filing |
| 2026-06-09 | Ford Harold Eugene Jr. | Option exercise | 24,116 | — | — | filing |
| 2026-06-09 | Phillips Holly L. | Option exercise | 24,116 | — | — | filing |
| 2026-06-09 | Nemirovsky Julian | Option exercise | 24,116 | — | — | filing |
| 2026-06-09 | DURNAN JAYMIE A | Option exercise | 24,116 | — | — | filing |
| 2026-06-09 | Nabel Gary J. | Option exercise | 24,116 | — | — | filing |
| 2026-03-25 | Miller Larry R.· General Counsel | Tax withholding | 3,526 | $4.99 | $17,594.74 | filing |
| 2026-03-25 | Miller Larry R.· General Counsel | Option exercise | 6,920 | $0.00 | $0.00 | filing |
| 2026-03-13 | Nguyen Diem· Chief Executive Officer | Tax withholding | 47,029 | $5.26 | $247,372.54 | filing |
| 2026-03-13 | Miller Larry R.· General Counsel | Tax withholding | 11,187 | $5.26 | $58,843.62 | filing |
| 2026-03-13 | Luckshire Daniel J· Executive VP & CFO | Tax withholding | 6,074 | $5.26 | $31,949.24 | filing |
| 2026-03-13 | Hruby Dennis E· EVP & Chief Scientific Officer | Tax withholding | 3,955 | $5.26 | $20,803.30 | filing |
| 2026-03-13 | Miller Larry R.· General Counsel | Option exercise | 21,261 | $0.00 | $0.00 | filing |
| 2026-03-13 | Luckshire Daniel J· Executive VP & CFO | Option exercise | 11,503 | $0.00 | $0.00 | filing |
| 2026-03-13 | Hruby Dennis E· EVP & Chief Scientific Officer | Option exercise | 11,445 | $0.00 | $0.00 | filing |
| 2026-03-13 | Nguyen Diem· Chief Executive Officer | Option exercise | 85,045 | $0.00 | $0.00 | filing |
| 2026-01-27 | Nguyen Diem· Chief Executive Officer | Tax withholding | 22,804 | $6.82 | $155,523.28 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.